Our top pick for
Otonomy Inc is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the NASDAQ and all prices are listed in US Dollars. Otonomy employs 56 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.89|
|52-week range||$1.14 - $6.98|
|50-day moving average||$1.74|
|200-day moving average||$1.97|
|Wall St. target price||$6.30|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.84|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.56%|
|1 month (2021-09-24)||7.39%|
|3 months (2021-07-23)||4.42%|
|6 months (2021-04-23)||-17.47%|
|1 year (2020-10-23)||-50.13%|
|2 years (2019-10-24)||-14.86%|
|3 years (2018-10-24)||2.25|
|5 years (2016-10-24)||16.55|
|Gross profit TTM||$-915,000|
|Return on assets TTM||-31.69%|
|Return on equity TTM||-94.45%|
|Market capitalisation||$107.1 million|
TTM: trailing 12 months
There are currently 451,623 Otonomy shares held short by investors – that's known as Otonomy's "short interest". This figure is 13.7% down from 523,233 last month.
There are a few different ways that this level of interest in shorting Otonomy shares can be evaluated.
Otonomy's "short interest ratio" (SIR) is the quantity of Otonomy shares currently shorted divided by the average quantity of Otonomy shares traded daily (recently around 236451.83246073). Otonomy's SIR currently stands at 1.91. In other words for every 100,000 Otonomy shares traded daily on the market, roughly 1910 shares are currently held short.
However Otonomy's short interest can also be evaluated against the total number of Otonomy shares, or, against the total number of tradable Otonomy shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Otonomy's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Otonomy shares in existence, roughly 10 shares are currently held short) or 0.0087% of the tradable shares (for every 100,000 tradable Otonomy shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Otonomy.
Find out more about how you can short Otonomy stock.
We're not expecting Otonomy to pay a dividend over the next 12 months.
Over the last 12 months, Otonomy's shares have ranged in value from as little as $1.14 up to $6.983. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Otonomy's is 1.818. This would suggest that Otonomy's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Otonomy, Inc. , a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.